Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism  

Studies have shown that many children with autism exhibit signs of oxidative stress, which causes cellular damage by the presence of highly reactive free radicals. Antioxidants may protect against the damaging effects of oxidative stress, and low antioxidant levels have been observed in children with autism. Nutritional supplementation by injections of the antioxidant methyl B12 is a current alternative medicine treatment for children with autism which has anecdotal reports of clinical improvements. This study will carry out an 8 week, double blind, placebo controlled clinical trial in 50 autistic children aged 3 to 8 years. Researchers will evaluate the subjects' behavioral responses to methyl B12 treatment. Additionally, they will monitor the blood levels of antioxidant metabolites to determine whether methyl B12 treatment can reverse the signs of oxidative stress observed in autism. This study will help determine whether methyl B12 is an effective treatment for core features of autism and may identify novel diagnostic markers for treatment responses in autistic subjects. Project Status
ONGOING

2010

Funder Autism Speaks
Fiscal Year Funding $127,500.00
Current Award Period 2009-2011
Project Number 3031
Principal Investigator Hendren, Robert
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Treatments)
Subcategory Complementary, Dietary, and Alternative
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4SC. Test safety and efficacy of at least five widely used interventions (e.g., nutrition, medications, assisted technologies, sensory integration, medical procedures) that have not been rigorously studied for use in ASD by 2012. IACC Recommended Budget: $27,800,000 over 5 years.
Federal or Private? Private
Institution University of California, Davis
State/Country California
Web Link 1 Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism | $150,000.00 | 2009 | 3031
Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism | $150,000.00 | 2008 | 3031